Anindita, P. D., Otsuka, Y., Lattmann, S., Ngo, K. H., Liew, C. W., Kang, C., Harris, R. S., Scampavia, L., Spicer, T. P., & Luo, D. (2024). A high-throughput cell-based screening method for Zika virus protease inhibitor discovery. SLAS Discovery, 29(5), 100164. https://doi.org/10.1016/j.slasd.2024.100164
Abstract:
Zika virus (ZIKV) continues to pose a significant global public health threat, with recurring regional outbreaks and potential for pandemic spread. Despite often being asymptomatic, ZIKV infections can have severe consequences, including neurological disorders and congenital abnormalities. Unfortunately, there are currently no approved vaccines or antiviral drugs for the prevention or treatment of ZIKV. One promising target for drug development is the ZIKV NS2B-NS3 protease due to its crucial role in the virus life cycle. In this study, we established a cell-based ZIKV protease inhibition assay designed for high-throughput screening (HTS). Our assay relies on the ZIKV protease's ability to cleave a cyclised firefly luciferase fused to a natural cleavage sequence between NS2B and NS3 protease within living cells. We evaluated the performance of our assay in HTS setting using the pharmacologic controls (JNJ-40418677 and MK-591) and by screening a Library of Pharmacologically Active Compounds (LOPAC). The results confirmed the feasibility of our assay for compound library screening to identify potential ZIKV protease inhibitors.
License type:
Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
Funding Info:
This research / project is supported by the National Institute of Allergy and Infectious Disease - National Institute of Allergy and Infectious Disease
Grant Reference no. : U19-AI171954
This research / project is supported by the Singapore Ministry of Education - Academic Research Fund Tier 2
Grant Reference no. : MOE-T2EP30220–0009